Browsing by Keyword : Dipeptidyl-Peptidase IV Inhibitors
Showing results 16 to 25 of 25
| Pub Year | | Title | Author(s) |
| 2022 | | Healthcare resource utilization in patients treated with empagliflozin in East Asia | 김대중, 하경화 |
| 2017 | | Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies | 김대중, 이광재 |
| 2021 | | Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study | 김대중, 하경화 |
| 2016 | | Protective Effects of Dipeptidyl Peptidase-4 Inhibitors on Progression of Diabetic Retinopathy in Patients with Type 2 Diabetes | 이기황, 정유리 |
| 2016 | | Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study | 김대중, 김혜진, 박래웅, 윤덕용, 이관우, 전자영, 한승진 |
| 2020 | | Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study | 김대중 |
| 2021 | | Safety and effectiveness of linagliptin in Korean patients with type 2 diabetes: A postmarketing surveillance study | 정윤석 |
| 2019 | | Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study | 김대중, 하경화 |
| 2018 | | Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study | 김대중, 김혜진, 이관우, 전자영, 한승진 |
| 2022 | | Sodium–glucose cotransporter 2 inhibitors do not increase the risk of fractures in real-world clinical practice in Korea: A national observational cohort study | 김대중, 최용준, 하경화 |
1
